Statement: There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 51/486 (10.49%)   ANEMIA 1/486 (0.21%)   NEUTROPENIA 4/486 (0.82%)   FIBRILLATION ATRIAL 1/486 (0.21%)   ABDOMINAL PAIN 2/486 (0.41%)   BLOATING 1/486 (0.21%)   BOWEL PERFORATION 1/486 (0.21%)   COLITIS 1/486 (0.21%)   DEHYDRATION 5/486 (1.03%)   DIARRHEA 5/486 (1.03%)   GASTRIC INFLAMMATION 1/486 (0.21%)   NAUSEA 3/486 (0.62%)   NAUSEA AND VOMITING 1/486 (0.21%) Adverse Events 2:
Secondary_evidence: Adverse Events 1:   Total: 17/40 (42.50%)   Anaemia 2/40 (5.00%)   Febrile Neutropenia 3/40 (7.50%)   Neutropenia 2/40 (5.00%)   Thrombocytopenia 5/40 (12.50%)   Pericardial Effusion 1/40 (2.50%)   Abdominal Pain Lower 1/40 (2.50%)   Disease Progression 6/40 (15.00%)   Fatigue 1/40 (2.50%)   Pyrexia 3/40 (7.50%)   Septic Shock 1/40 (2.50%)   Streptococcal Infection 1/40 (2.50%)